A Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Healthy Subjects, and Subjects With Mild to Moderate Atopic Dermatitis
Latest Information Update: 15 Dec 2023
At a glance
- Drugs AR 100 Arjil Pharmaceuticals (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Arjil Pharmaceuticals
Most Recent Events
- 09 Jan 2020 New trial record